No description available.

No description available.

Conselho Nacional de Desenvolvimento CientÃfico e TecnolÃgico / INTRODUÃÃO: O papel do LPS na defesa da mucosa gÃstrica ainda nÃo està estabelecido. OBJETIVOS: 1-Verificar o efeito protetor do LPS na lesÃo gÃstrica (LG), na infiltraÃÃo de neutrÃfilos (IN), no aumento da adesÃo leucocitÃria, na diminuiÃÃo dos nÃveis de GSH induzidos por indometacina (INDO) em ratos; 2-Investigar o papel da COX-2, NOSi e dos canais de K sensÃveis ao ATP (KATP) na gastroproteÃÃo do LPS na gastropatia por INDO. MÃTODOS: Os ratos foram tratados com LPS da E. coli (30, 100 ou 300 g/Kg, e.v.). ApÃs 6 hs, foi administrado INDO (20mg/Kg, p.o.). Decorridas 3 hs, o sangue foi colhido para determinaÃÃo do leucograma. Posteriormente, os ratos foram sacrificados e a LG foi aferida. Fragmentos do estÃmago foram retirados para avaliaÃÃo da atividade de mieloperoxidase (MPO) e determinaÃÃo dos nÃveis de glutationa (GSH). A adesÃo e o rolling dos leucÃcitos foram avaliados por microscopia intravital. Diferentes grupos foram tratados com rofecoxib, L-NAME, aminoguanidina, dexametasona, glibenclamida, diazÃxido ou glibenclamida + diazÃxido. ApÃs 3 horas da administraÃÃo de INDO (20mg/Kg, p.o.), foram avaliadas a LG, a MPO e GSH. RESULTADOS: LPS reduziu a LG e o aumentou a MPO induzidas por INDO de forma dose-dependente, com o efeito mÃximo na dose de 300 g/Kg e no tempo de 6 hs. O prÃ-tratamento com LPS induziu uma neutrofilia na gastropatia induzida pela INDO. LPS reverteu à queda dos nÃveis de GSH no estÃmago com INDO. O tratamento com LPS diminui a adesÃo e aumentou o rolling dos leucÃcitos quando comparado com o tratado com INDO. Rofecoxib, L-NAME, aminoguanidina ou dexametasona nÃo reverteram o efeito protetor do LPS. Glibenclamida, mas nÃo diazÃxido, reverteu o efeito protetor do LPS na gastropatia induzida por INDO, aumentando de forma significativa a LG, MPO e diminuindo a GSH. A associaÃÃo de glibenclamida com diazÃxido nÃo reverteu o efeito protetor do LPS. CONCLUSÃES: LPS protege contra a LG por INDO, atravÃs da inibiÃÃo da IN por uma diminuiÃÃo da adesÃo de leucÃcitos ao endotÃlio e por um aumento dos nÃveis de GSH no estÃmago. Este evento dependente da abertura de KATP. Nossos dados tambÃm sugerem que a atividade de COX-2 e NOSi nÃo estÃo envolvidos no efeito protetor do LPS. / INTRODUCTION: The role of the LPS in the defense of the gastric mucosa is still not established. AIMS: To verify the protective effect of the LPS in the gastric damage (GD), in the neutrophil infiltration (NI), in the increase of the leukocyte of adhesion, in the reduction of the induced glutathione levels for indomethacin (INDO) in rats and to investigate the role of the COX-2, NOSi and of ATP-sensitive k channels (KATP) in the protective effect of LPS administration on INDO- induced gastropathy. METHODS: The rats were treated with LPS of E. coli (30, 100 or 300 mg/Kg, e.v.). After 6 hs, INDO was administrated (20mg/Kg, p.o.). 3 hs later, the blood was harvested for determination the total and differential number of white blood cell counts. Later, the rats had been sacrificed and the GD was surveyed. Piece of the stomach had been removed for evaluation of the MPOactivity and determination of the GSH levels. The adhesion and rolling of the leukocytes had been evaluated by intravital microscopy. Different groups were treated with rofecoxib, L-NAME, aminoguanidine, dexamethasone, glibenclamide, diazoxide or glibenclamide + diazoxide. After 3 hs of the administration of INDO (20mg/Kg, p.o.), had been evaluated the GD, MPO and GSH. RESULTS: LPS reduced dose- dependently INDO- induced GD and increase in MPO, with the maximal effect at the dose of 300 g/kg and in the time of 6 hs. The LPS treatment neutrophilia induced in INDO induced gastropathy. LPS reverted to the fall of the GSH levels in the stomach with INDO. The LPS treatment decreased the adhesion and increased rolling of the leukocytes when compared with the INDO treated. Rofecoxib, L-NAME, aminoguanidine or dexamethasona had not reverted the protective effect of the LPS. Glibenclamide, but not diazoxide, reverted the protective effect of the LPS in the induced gastropathy for INDO, increasing of significant form the GD, MPO and decreasing the GSH. The diazoxide + glibenclamide association of with did not revert the protective effect of the LPS. CONCLUSIONS: LPS protects against INDO induced GD, through the inhibition of the NI for a reduction of the adhesion of leukocytes to the endothelin and for an increase of the GSH levels in the stomach. This dependent event of the KATP opening. Our data also suggest that the activity of COX-2 and NOSi are not involved in the protective effect of the LPS.

ATP dependent chromatin remodelers use the energy from ATP hydrolysis to move, disassemble or alter the composition of nucleosomes. Though all remodelers share a conserved ATP hydrolysis and DNA translocase domain, their biochemical actions and in-vivo characteristics differ because of their subunits and accessory domains in the catalytic subunit that regulate its activity. Understanding how these domains contribute to remodeler regulation in terms of substrate interaction and regulation of the catalytic subunit is therefore important to understanding what causes a remodeler to behave differently, and what are the mechanistic underpinnings of such behavior. In this study we have addressed these questions using the SWI/SNF remodeler from budding yeast (Saccharomyces cerevisiae) to explore how different remodelers compare to SWI/SNF in terms of nucleosome interaction. Using a chemical based histone – remodeler photo-crosslinking and labeling approach, we show that different remodelers contact nucleosomes in patterns unique to their functions, and even remodelers that belong to the same family interact with nucleosomes in a unique manner to accomplish their respective remodeling results. In addition we delineate the functions of the AT hook motifs in the catalytic subunit of SWI/SNF using in-vitro and in-vivo techniques. We demonstrate the necessity of the regulatory action of the motif in the context of SWI/SNF remodeling due to its requirement for efficient ATP hydrolysis by the catalytic domain and therefore efficient remodeling. We also demonstrate for the first time that SWI/SNF in yeast is involved in transcriptional repression with evidence that the AT hook alters SWI/SNF activity at particular genomic regions. Regulation of SWI/SNF activity is an increasingly important topic of study, with mutations that cause SWI/SNF dysfunction being implicated in a large number of cancers and neurological diseases. We attempt to find out the biochemical implications of mutations in the catalytic, SnAC and AT hook motifs with respect to SWI/SNF activity. Taken together, this study provides an insight into some of the different mechanisms in which remodelers are regulated using budding yeast as a model system.

Chromatin remodelers utilize the energy derived from ATP hydrolysis to mobilize nucleosomes. ISWI remodelers mobilize and evenly space nucleosomes to regulate gene expression. ISW2, an ISWI remodeler in yeast, has been shown to reposition nucleosome near promoter regions and represses both mRNA and antisense non coding RNA transcription. ISW2 is composed of four subunits and the catalytic Isw2 subunit consists of several conserved domains. The highly conserved ATPase domain is present at the N-terminus whereas the conserved HAND, SANT and SLIDE domain are towards the carboxyl terminal end of Isw2. Nucleosome mobilization by ISW2 requires both extranucleosomal DNA and the N-terminal tail of histone H4. DNA crosslinking and peptide mapping revealed that the ATPase domain contacts nucleosome two helical turns away (SHL2) from dyad to a site close to the H4 tail, whereas the HAND, SANT and SLIDE domain contact a 30bp stretch of DNA comprising the edge of nucleosome and ~20bp of extranucleosomal DNA. The ATPase domain and the C-terminal domains were investigated for their role in regulation of ISW2 activity both in-vitro and in-vivo. It appears that there are distinct modes of ISW2 regulation by these domains. Mutation of a patch of five acidic amino acids on the region of ATPase domain that contact SHL2 was found to be crucial for both ISW2 remodeling and nucleosome stimulated ATPase activity. Acidic patch mutant ISW2 was unable to mobilize nucleosome or hydrolyze ATP in absence of H4 tail. This indicates that the region of ATPase domain contacting nucleosome at SHL2 and H4 tail act in two separate and independent pathways to regulate ISW2 remodeling. Both HAND and SLIDE domain were shown to crosslink entry/exit site and linker DNA respectively. The roles of C-terminal domains were investigated either by deletion of the individual domain or mutation of conserved basic residues on the surface of these domains that are suspected to interact extranucleosomal with DNA. Deletion of HAND domain had minimal effect on in vitro ISW2 activity, however whole genome transcription analysis revealed one key role of this domain in ISW2 regulation. In absence of HAND domain, ISW2 had minimal role on repression of genes that were RPD3 (co-factor) dependent, however significantly derepressed genes that were RPD3 independent. At these loci, nucleosome positions were altered and ISW2 recruitment was reduced in absence of a functional HAND domain. Thus the HAND domain regulates recruitment and remodeling of ISW2 at those genes where ISW2 acts independent of other cofactors. The SANT domain, C-terminal to HAND domain, appears to control the "step size" of nucleosome remodeling and was found to be required for processive nucleosome remodeling by ISW2. Both H4 tail and SANT domain appear to control two distinct stages of ISW2 remodeling. A long alpha helical spacer separates SANT domain from SLIDE domain. SLIDE domain was found to be the protein-protein interaction domain that interacts with accessory Itc1 subunit to maintain ISW2 complex integrity. The two ways by which SLIDE domain regulate ISW2 is by binding or recruitment of ISW2 to promoter regions and additionally by binding independent regulation of both ATPase and remodeling activity. The remodeling mechanism of ISW2 was further compared with another ISWI type remodeler in yeast, Isw1a; using time resolved nucleosome remodeling combined with high resolution site specific histone DNA crosslinking at six different nucleosomal positions to track the movement of the nucleosomes. Nucleosome remodeled by the same remodeler showed discontinuous nucleosome movement between two tracking points indicating formation of small "bulges". One key difference in remodeling mechanism was that although both ISW2 and Isw1a moved nucleosomes towards longer linker DNA, only Isw1a remodeled nucleosomes "backtracked" ~11bp during remodeling. Backtracking of remodeling was prominently observed at nucleosomal regions in close proximity to translocase binding sites suggesting the potentially different mechanisms shared by similar remodeling complexes.

No description available.

No description available.

O diabete melito é um grupo de doenças metabólicas caracterizadas por hiperglicemia, resultado de deficiências na secreção de insulina, em sua acção ou ambos. A pioglitazona é um hipoglicemiante oral, da classe da tiazolidinedionas, que atuam pela ligação aos receptores nucleares PPARY melhorando o estado de resistência a insulina. Acredita-se que a pioglitazona também restauram a capacidade da célula beta pancreática de secretar insulina, cuja atividade é regulada pelos canais de potássio dependente de ATP (KATP) e suas subunidades SUR1 e KIR6.2. Este estudo teve como objetivo iniciar um estudo farmacogenômico da pioglitazona em indivíduos diabéticos tipo 2 e na expressão dos genes PPARY PPARY2, SUR1 e KIR6.2 no sangue periférico e no tecido adiposo e associá-los com os polimorfismo Pro12Ala e C161T do gene PPARY. Foram selecionados 36 pacientes diabéticos do tipo 2 e 16 pacientes normoglicêmicos, no Instituto Dante Pazzanese de Cardiologia. Os indivíduos diabéticos foram tratados com pioglitazona (15, 30 e 45 mg/ dia/ via oral) por 16 semanas. Foram colhidas amostras de tecido adiposo por biopsia e de sangue, antes e após o tratamento para determinação de exames laboratoriais, extração de DNA genômico e de RNA total. Os polimorfismos foram detectados pela técnica de PCR-RFLP e a expressão de mRNA foi quantificada e avaliada por RT-PCR em tempo real. Após tratamento com pioglitazona, observou-se no sangue periférico aumento de expressão de mRNA do PPARY, PPARY2 e KIR6.2, e diminuição da expressão de SUR1. Dados de analises no sangue periférico, demostraram que variação da expressão de mRNA do PPARY foi inversamente correlacionada com as variações de insulina, Homa-IR, Homa-Beta e positivamente com Colesterol Total. Em relação ao gene PPARY2, foi inversamente correlacionada com colesterol total. Variação da expressão de SUR1 foi inversamente correlacionada com Hb1Ac, Homa-IR, Homa-Beta e positivamente com insulina. Não foram detectadas diferenças entre a expressão de mRNA de KIR6.2 e parâmetros bioquímicos em resposta às variações pioglItazona. Não houve diferença da resposta terapêutica e presença dos polimorfismos Pro12Ala e C161T. Após o tratamento, no tecido adiposo, a expressão de mRNA de PPARY aumentou. Não foram observadas diferenças na expressão dos genes PPARY2, SUR1 e KIR6.2. Em leucócitos totais de sangue periférico, pioglitazona demonstrou regular a expressão dos genes PPARY e PPARY2, e também atuando sobre as subunidades SUR1 e KIR6.2, possivelmente restaurando a função secretora das células beta. No tecido adiposo, o tratamento confirma a atuação da pioglitazona sobre PPARY, melhorando o estado de resistência a insulina. / The diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia, the result from insulin secretion or action deficiency, or both. Pioglitazone is an oral hypoglycemic drug, included in the class of thiazolidinediones, which work by binding to nuclear receptors PPARY nuclear what improve the state of resistance to insulin. Pioglitazone may also restore the ability of the pancreatic beta cell to secrete insulin, process which is regulated thought ATP dependent potassium channels (KATP) and its subunits SUR1 and KIR6.2. The aim of our study was to begin a pharmacogenomic study of pioglitazone in type 2 diabetes patients by the expression of PPARY, PPARY2, SUR1 and KIR6.2 genes in peripheral blood leukocytes and fatty tissue and its association with the PPARY Pro12Ala and C161T polimorphisms. 36 type 2 diabetes and 16 normoglycemic patients were selected at the Dante Pazzanese Institute of Cardiology. The diabetic ones were treated with pioglitazone (15, 30 and 45 mg/ daily /orally) for 16 weeks. Samples of adipose - obtained through biopsy - and blood were collected before and after treatment to aim to laboratory experiments, DNA extraction and total RNA extraction. The polymorphisms were detected by the PCR-RFLP technique while the mRNA expression was quantified and evaluated by Real Time RT-PCR. After pioglitazone treatment, the expression of the PPARY, PPARY2 and KIR6.2 genes increased, while SUR1 decreased, all of them quantified in peripheral blood. Peripheral blood data has demonstrated that the variation of expression of PPARYmRNA is inversely correlated with insulin concentrations, Homa-IR, Homa-Beta and positively correlated with total cholesterol concentrations. Differently, PPARY2 gene expression was inversely correlated with total cholesterol blood concentrations. Variations in SUR1 mRNA expression were inversely correlated with Hb1Ac, Homa-IR, Homa-Beta and positively correlated with insulin. No differences were found between the KIR6.2 expression and biochemical parameters due to pioglItazone treatment. There was no difference in response to the treatment response and no Pro12Ala and C161T polymorphisms were noticed. After the treatment, the expression of PPARY gene increased in fatty tissue. No data showed differences in the expression of genes PPARY2, SUR1 and KIR6.2. Pioglitazone regulates the expression of genes PPARY and PPARY2, and also acts on the SUR1 and KIR6.2 subunits in total peripheral blood leukocyte likely restoring the function of secreting beta pancreatic cells. In adipose, the treatment reassures the functions of pioglitazone on PPARY, improving the state of insulin resistance.

O diabete melito é um grupo de doenças metabólicas caracterizadas por hiperglicemia, resultado de deficiências na secreção de insulina, em sua acção ou ambos. A pioglitazona é um hipoglicemiante oral, da classe da tiazolidinedionas, que atuam pela ligação aos receptores nucleares PPARY melhorando o estado de resistência a insulina. Acredita-se que a pioglitazona também restauram a capacidade da célula beta pancreática de secretar insulina, cuja atividade é regulada pelos canais de potássio dependente de ATP (KATP) e suas subunidades SUR1 e KIR6.2. Este estudo teve como objetivo iniciar um estudo farmacogenômico da pioglitazona em indivíduos diabéticos tipo 2 e na expressão dos genes PPARY PPARY2, SUR1 e KIR6.2 no sangue periférico e no tecido adiposo e associá-los com os polimorfismo Pro12Ala e C161T do gene PPARY. Foram selecionados 36 pacientes diabéticos do tipo 2 e 16 pacientes normoglicêmicos, no Instituto Dante Pazzanese de Cardiologia. Os indivíduos diabéticos foram tratados com pioglitazona (15, 30 e 45 mg/ dia/ via oral) por 16 semanas. Foram colhidas amostras de tecido adiposo por biopsia e de sangue, antes e após o tratamento para determinação de exames laboratoriais, extração de DNA genômico e de RNA total. Os polimorfismos foram detectados pela técnica de PCR-RFLP e a expressão de mRNA foi quantificada e avaliada por RT-PCR em tempo real. Após tratamento com pioglitazona, observou-se no sangue periférico aumento de expressão de mRNA do PPARY, PPARY2 e KIR6.2, e diminuição da expressão de SUR1. Dados de analises no sangue periférico, demostraram que variação da expressão de mRNA do PPARY foi inversamente correlacionada com as variações de insulina, Homa-IR, Homa-Beta e positivamente com Colesterol Total. Em relação ao gene PPARY2, foi inversamente correlacionada com colesterol total. Variação da expressão de SUR1 foi inversamente correlacionada com Hb1Ac, Homa-IR, Homa-Beta e positivamente com insulina. Não foram detectadas diferenças entre a expressão de mRNA de KIR6.2 e parâmetros bioquímicos em resposta às variações pioglItazona. Não houve diferença da resposta terapêutica e presença dos polimorfismos Pro12Ala e C161T. Após o tratamento, no tecido adiposo, a expressão de mRNA de PPARY aumentou. Não foram observadas diferenças na expressão dos genes PPARY2, SUR1 e KIR6.2. Em leucócitos totais de sangue periférico, pioglitazona demonstrou regular a expressão dos genes PPARY e PPARY2, e também atuando sobre as subunidades SUR1 e KIR6.2, possivelmente restaurando a função secretora das células beta. No tecido adiposo, o tratamento confirma a atuação da pioglitazona sobre PPARY, melhorando o estado de resistência a insulina. / The diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia, the result from insulin secretion or action deficiency, or both. Pioglitazone is an oral hypoglycemic drug, included in the class of thiazolidinediones, which work by binding to nuclear receptors PPARY nuclear what improve the state of resistance to insulin. Pioglitazone may also restore the ability of the pancreatic beta cell to secrete insulin, process which is regulated thought ATP dependent potassium channels (KATP) and its subunits SUR1 and KIR6.2. The aim of our study was to begin a pharmacogenomic study of pioglitazone in type 2 diabetes patients by the expression of PPARY, PPARY2, SUR1 and KIR6.2 genes in peripheral blood leukocytes and fatty tissue and its association with the PPARY Pro12Ala and C161T polimorphisms. 36 type 2 diabetes and 16 normoglycemic patients were selected at the Dante Pazzanese Institute of Cardiology. The diabetic ones were treated with pioglitazone (15, 30 and 45 mg/ daily /orally) for 16 weeks. Samples of adipose - obtained through biopsy - and blood were collected before and after treatment to aim to laboratory experiments, DNA extraction and total RNA extraction. The polymorphisms were detected by the PCR-RFLP technique while the mRNA expression was quantified and evaluated by Real Time RT-PCR. After pioglitazone treatment, the expression of the PPARY, PPARY2 and KIR6.2 genes increased, while SUR1 decreased, all of them quantified in peripheral blood. Peripheral blood data has demonstrated that the variation of expression of PPARYmRNA is inversely correlated with insulin concentrations, Homa-IR, Homa-Beta and positively correlated with total cholesterol concentrations. Differently, PPARY2 gene expression was inversely correlated with total cholesterol blood concentrations. Variations in SUR1 mRNA expression were inversely correlated with Hb1Ac, Homa-IR, Homa-Beta and positively correlated with insulin. No differences were found between the KIR6.2 expression and biochemical parameters due to pioglItazone treatment. There was no difference in response to the treatment response and no Pro12Ala and C161T polymorphisms were noticed. After the treatment, the expression of PPARY gene increased in fatty tissue. No data showed differences in the expression of genes PPARY2, SUR1 and KIR6.2. Pioglitazone regulates the expression of genes PPARY and PPARY2, and also acts on the SUR1 and KIR6.2 subunits in total peripheral blood leukocyte likely restoring the function of secreting beta pancreatic cells. In adipose, the treatment reassures the functions of pioglitazone on PPARY, improving the state of insulin resistance.

Cellular and tissue characteristics are results of dynamic regulation of gene expression. DNA wrapped into proteins, referred to as chromatin, requires involvement of mechanisms guiding accessibility of specific sequences. In higher organisms, chromatin remodeling proteins are indispensable in regulating chromatin structure including ISWI ATPase SMARCA5. SMARCA5 is involved in almost any transaction on DNA including transcription, however precise in vivo role of SMARCA5 in these processes remains unknown. To advance understanding of specific role of SMARCA5 in the development of chromatin structure during transcription we devised cellular model in which SMARAC5 level is manipulated while chromatin structure development and transcriptional response are monitored. Our data indicate that the transfected DNA template that is transcribed is enriched with histone H3 and its specific methylation of Histone H3 lysine (K) 4, a mark of active chromatin structure. Overexpression of SMARCA5 results within the reporter gene coding sequence in ~2,5-3 fold increase of both H3 occupancy an its modification H3K4Me3. Increased DNA template commitment into chromatinization is associated with repression of reporter gene expression. These results are supported by studies indicating dynamic development of nucleosomal...